Compare iShares Core MSCI EAFE ETF (IEFA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Viatris Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.91, while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while iShares Core MSCI EAFE ETF pays none, and Viatris Inc is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals.
| IEFA | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $17.39 |
52-Week Low | $81.70 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% with a bearish technical signal. The ETF focuses on developed international markets excluding North America, offering a competitive 0.07% expense ratio and 3.30% dividend yield. Recent performance shows 19.9% one-year gains, though trailing SPGM's 23.1%. Technical indicators show mixed signals with RSI in neutral territory and key support at $94.
Outlook remains cautious due to bearish technical momentum and developed market rate hikes. The fund provides diversification benefits against US concentration risk but faces currency volatility. Analyst sentiment is mixed, with some favoring broader international exposure through VXUS or IXUS for comprehensive global coverage.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
